Prosecution Insights
Last updated: August 06, 2026

Peptilogics Inc.

5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
3
Non-Final OAs
1
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (60%)
2
Medium (40%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only1 (20%)
§101 + other1 (20%)
§103 only1 (20%)
Double-patenting + other1 (20%)
Multi-statute (no §101)1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
STEELE, AMBER D 1 59.0% +9.7%
ZEMAN, MARY K 1 59.1% +34.6%
WOITACH, JOSEPH T 1 50.0% +27.5%
KRIANGCHAIVECH, KETTIP 1 19.2% +29.4%
KONOPELSKI SNAVEL, SARA ELIZABETH 1 28.6% +33.3%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17403194 ARTIFICIAL INTELLIGENCE ENGINE FOR GENERATING CANDIDATE DRUGS USING EXPERIMENTAL VALIDATION AND PEPTIDE DRUG OPTIMIZATION ZEMAN, MARY K 45d overdue
17339598 ARTIFICIAL INTELLIGENCE ENGINE ARCHITECTURE FOR GENERATING CANDIDATE DRUGS WOITACH, JOSEPH T 25d overdue
17319839 GENERATING ANTI-INFECTIVE DESIGN SPACES FOR SELECTING DRUG CANDIDATES KRIANGCHAIVECH, KETTIP 4d overdue
16980295 TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES KONOPELSKI SNAVEL, SARA ELIZABETH

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17403194 ARTIFICIAL INTELLIGENCE ENGINE FOR GENERATING CANDIDATE DRUGS USING EXPERIMENTAL VALIDATION AND PEPTIDE DRUG OPTIMIZATION ZEMAN, MARY K 45d overdue
17339598 ARTIFICIAL INTELLIGENCE ENGINE ARCHITECTURE FOR GENERATING CANDIDATE DRUGS WOITACH, JOSEPH T 25d overdue
17319839 GENERATING ANTI-INFECTIVE DESIGN SPACES FOR SELECTING DRUG CANDIDATES KRIANGCHAIVECH, KETTIP 4d overdue
16980295 TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES KONOPELSKI SNAVEL, SARA ELIZABETH

Top Art Units

Art UnitApps
1658 2
1686 2
1687 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18290214 Engineered Antimicrobial Peptides and Usage Thereof STEELE, AMBER D 1658 §102§103§112DP Non-Final OA Pending Nov 10, 2023
17403194 ARTIFICIAL INTELLIGENCE ENGINE FOR GENERATING CANDIDATE DRUGS USING EXPERIMENTAL VALIDATION AND PEPTIDE DRUG OPTIMIZATION ZEMAN, MARY K 1686 §103§112 Final Rejection 45d overdue Pending Aug 16, 2021
17339598 ARTIFICIAL INTELLIGENCE ENGINE ARCHITECTURE FOR GENERATING CANDIDATE DRUGS WOITACH, JOSEPH T 1687 §101Other Non-Final OA 25d overdue Pending Jun 04, 2021
17319839 GENERATING ANTI-INFECTIVE DESIGN SPACES FOR SELECTING DRUG CANDIDATES KRIANGCHAIVECH, KETTIP 1686 §101§103§112 Non-Final OA 4d overdue Pending May 13, 2021
16980295 TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES KONOPELSKI SNAVEL, SARA ELIZABETH 1658 §103Other Non-Final OA Pending Sep 11, 2020

Managing Peptilogics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month